Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) by 21.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,887 shares of the company’s stock after buying an additional 339 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Janux Therapeutics were worth $87,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JANX. Point72 Asset Management L.P. purchased a new position in Janux Therapeutics during the second quarter worth approximately $5,715,000. Blue Owl Capital Holdings LP purchased a new position in Janux Therapeutics in the second quarter worth approximately $1,676,000. The Manufacturers Life Insurance Company increased its stake in Janux Therapeutics by 234.7% during the second quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company’s stock worth $1,007,000 after acquiring an additional 16,864 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Janux Therapeutics in the second quarter valued at $215,000. Finally, Samlyn Capital LLC lifted its stake in shares of Janux Therapeutics by 9.6% in the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock valued at $13,602,000 after purchasing an additional 28,312 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on JANX shares. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a research report on Monday, August 19th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Wedbush restated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, UBS Group assumed coverage on Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective on the stock. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $66.44.

Janux Therapeutics Price Performance

JANX opened at $55.87 on Tuesday. The business has a fifty day moving average price of $48.28 and a 200 day moving average price of $46.19. Janux Therapeutics, Inc. has a 12 month low of $5.65 and a 12 month high of $65.60. The stock has a market capitalization of $2.91 billion, a price-to-earnings ratio of -61.40 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The firm had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. The business’s revenue for the quarter was up 709.1% on a year-over-year basis. On average, research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 1,200,000 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were acquired at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the acquisition, the director now owns 9,317,246 shares in the company, valued at $416,946,758.50. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Ra Capital Management, L.P. bought 1,200,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were purchased at an average cost of $44.75 per share, with a total value of $53,700,000.00. Following the transaction, the director now directly owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now owns 67,592 shares in the company, valued at $3,106,528.32. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 420,610 shares of company stock valued at $19,288,666. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.